Olanzapine

Zyprexa, Zyprexa Zydis, Lybalvi, Symbyax

Antipsychotic • Second-generation (atypical) antipsychotic

Premium

QT RiskCNS Depressant

Half-life

21-54 hours

Protein Binding

93%

Metabolized By

CYP1A2, CYP2D6

External

Drugs.com

Boxed warning

Increased mortality in elderly patients with dementia-related psychosis
Severe sedation with IM olanzapine + benzodiazepine

Clinical alerts

Boxed warning

2 boxed warnings

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Anticholinergic

Adds to anticholinergic burden, particularly in older patients

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Antagonizes multiple receptors including D2, 5-HT2A, H1, and muscarinic receptors

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Breast Cancer
·Insulin Resistance
·Menstrual Cycle
·Type 2 Diabetes
·Antipsychotics

Interactions

No curated interaction pairs are recorded for Olanzapine. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Significant weight gain
Metabolic syndrome
Hyperglycemia
Sedation
Dyslipidemia

Food, alcohol & herbal

Food

Smoking (CYP1A2 induction) decreases olanzapine levels

Alcohol · major

Additive CNS depression

Pharmacokinetics

Half-life: 21-54 hours
Protein binding: 93%
Metabolised by: CYP1A2, CYP2D6

Pregnancy & lactation

Not recorded for Olanzapine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Olanzapine

Zyprexa, Zyprexa Zydis, Lybalvi, Symbyax

Antipsychotic • Second-generation (atypical) antipsychotic

Premium

QT RiskCNS Depressant

Half-life

21-54 hours

Protein Binding

93%

Metabolized By

CYP1A2, CYP2D6

External

Drugs.com

Boxed warning

Increased mortality in elderly patients with dementia-related psychosis
Severe sedation with IM olanzapine + benzodiazepine

Clinical alerts

Boxed warning

2 boxed warnings

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Anticholinergic

Adds to anticholinergic burden, particularly in older patients

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Antagonizes multiple receptors including D2, 5-HT2A, H1, and muscarinic receptors

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Breast Cancer
·Insulin Resistance
·Menstrual Cycle
·Type 2 Diabetes
·Antipsychotics

Interactions

No curated interaction pairs are recorded for Olanzapine. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Significant weight gain
Metabolic syndrome
Hyperglycemia
Sedation
Dyslipidemia

Food, alcohol & herbal

Food

Smoking (CYP1A2 induction) decreases olanzapine levels

Alcohol · major

Additive CNS depression

Pharmacokinetics

Half-life: 21-54 hours
Protein binding: 93%
Metabolised by: CYP1A2, CYP2D6

Pregnancy & lactation

Not recorded for Olanzapine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement

Olanzapine Drug Profile | PharmaGraphX